Actinium Pharmaceuticals (ATNM) is a clinical-stage biopharmaceutical company. CEO Sandesh Seth discusses ATNM which is developing a new radiotherapy candidate for cancer patients. The company released promising results from trials of its radiotherapy candidate IOMAB-B which could help patients with relapsed or refractory acute myeloid leukemia receive bone marrow transplants. He then goes over the outlook for the company. Tune in to find out more about the stock market today.
14 Nov 2022
The Watch List
22 Jan 2023
The Watch List
17 Feb 2023
Market On Close
23 Jan 2023
The Watch List
31 Jan 2023
Market On Close
24 Feb 2023